Wells Fargo & Company Eq Rx, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$1.66 - $2.31 $85,914 - $119,556	-51,756 Reduced 22.97%	173,596 $385,000
Q2 2023 Aug 15, 2023	BUY	$1.61 - $1.96 $9,618 - $11,709	5,974 Added 2.72%	225,352 $419,000
Q1 2023 May 12, 2023	BUY	$1.8 - $2.83 $393,746 - $619,056	218,748 Added 34721.9%	219,378 $425,000
Q4 2022 Feb 13, 2023	SELL	$2.05 - $5.5 $7,722 - $20,718	-3,767 Reduced 85.67%	630 $1,000
Q3 2022 Nov 14, 2022	BUY	$0.94 - $5.99 $125 - $796	133 Added 3.12%	4,397 $22,000
Q2 2022 Aug 12, 2022	BUY	$3.2 - $5.69 $9,225 - $16,404	2,883 Added 208.76%	4,264 $20,000
Q1 2022 May 16, 2022	BUY	$2.8 - $7.39 $3,866 - $10,205	1,381 New	1,381 $6,000

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.